Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors

NCT04390737 is registered in ClinicalTrials.gov with Haihe Biopharma Co., Ltd. as lead sponsor.

NCT NCT04390737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04390737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors
Lead sponsor
Haihe Biopharma Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 8, 2020
Completion date
December 31, 2028
Enrollment
254 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, epithelioid sarcoma, fl lymphoma, peripheral t cell lymphoma